Nature Methods Names Spatial Proteomics "Method of the Year 2024" — Akoya Biosciences Celebrates Industry Milestone
Nature Methods Names Spatial Proteomics "Method of the Year 2024" — Akoya Biosciences Celebrates Industry Milestone
MARLBOROUGH, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) ("Akoya"), The Spatial Biology Company, announced that Nature Methods, one of the world's leading scientific journals, has selected spatial proteomics as its prestigious "Method of the Year 2024", recognizing the transformative potential of this approach in advancing biological research and medicine. As a global leader in spatial proteomics, with the industry's largest installed base of 1300 instruments and nearly 1600 publications citing its technologies, Akoya celebrates this milestone as a testament to the technology's impact and reaffirms its dedication to driving innovation in this rapidly evolving field.
马尔堡，马萨诸塞州，2024年12月09日（环球新闻）-- Akoya生物科学公司（纳斯达克：AKYA）（"Akoya"），空间生物学公司，宣布世界领先的科学期刊之一《自然方法》已将空间蛋白组学选为其2024年"年度方法"，以此认可这一方法在推动生物研究和医学方面的变革潜力。作为空间蛋白组学的全球领导者，Akoya拥有1300台仪器的行业最大装机基础和近1600篇引用其技术的出版物，该公司庆祝这一里程碑，证明了这一技术的影响，并重申了其在快速发展的领域推动创新的承诺。
Spatial proteomics provides scientists with the ability to map the spatial distribution of proteins within cells and tissues, revealing insights into cellular mechanisms, tissue architecture, and disease progression. Its applications span oncology, immunotherapy, neuroscience, drug development, and more, delivering unprecedented resolution and depth to biological research. Akoya offers complete end-to-end spatial proteomic solutions with instruments, reagents, software and services serving customers that span from discovery to diagnostics. The PhenoCycler-Fusion is an ultrahigh-plex platform for spatial discovery while the PhenoImager HT is a high-throughput platform for translational and clinical applications.
空间蛋白组学为科学家提供了绘制细胞和组织内蛋白空间分布的能力，揭示了细胞机制、组织结构和疾病进展的见解。其应用涵盖肿瘤学、免疫疗法、神经科学、药物开发等多个领域，为生物研究提供了前所未有的分辨率和深度。Akoya提供完整的端到端空间蛋白组学解决方案，包括仪器、试剂、软件和服务，服务于从发现到诊断的客户。PhenoCycler-Fusion是一种超高通量的平台，用于空间发现，而PhenoImager Ht是用于转化和临床应用的高通量平台。
"At Akoya, we are proud to be at the forefront of spatial proteomics, revolutionizing how scientists understand complex biological systems," said Brian McKelligon, CEO of Akoya Biosciences. "Spatial proteomics being recognized by Nature Methods underscores the pivotal role this method plays in driving scientific breakthroughs and further validates Akoya's singular focus on driving continued advancement in our platforms for the betterment of our customers and ultimately patients."
"在Akoya，我们自豪地站在空间蛋白组学的最前沿，彻底改变科学家理解复杂生物系统的方式，"Akoya生物科学公司首席执行官布莱恩·麦凯利根（Brian McKelligon）说。"空间蛋白组学被《自然方法》认可，强调了这一方法在推动科学突破中发挥的关键作用，并进一步验证了Akoya专注于推动我们平台持续进步的独特定位，以造福我们的客户，最终造福患者。"
Customer and KOL Perspectives
客户及关键意见领袖观点
Esteemed researchers and thought leaders in the scientific community have recognized the transformative potential of spatial proteomics and the contributions of Akoya Biosciences in this space:
在科学社区中，杰出的研究人员和思想领袖们认识到了空间蛋白质组学的变革潜力，以及Akoya Biosciences在这一领域的贡献：
Dr. Garry Nolan, Rachford and Carlota Harris Professor, Department of Pathology, Stanford University, Co-founder of Akoya Biosciences and Chair of Akoya's Scientific Advisory Board commented:
斯坦福大学病理学系的拉克福德和卡洛塔·哈里斯教授、Akoya Biosciences的联合创始人和Akoya科学顾问委员会主席加里·诺兰博士评论道：
"Spatial proteomics represents a paradigm shift in our ability to understand complex tissue architecture and cellular interactions in their native context. Akoya's technology allows us to explore the intricate relationships between cells and their environments, unlocking insights that were previously unattainable and driving breakthroughs in both basic science and clinical applications."
“空间蛋白质组学在我们理解复杂组织结构和细胞相互作用的能力上代表了一次范式转变。Akoya的技术让我们能够探索细胞与其环境之间的复杂关系，揭示了之前不可获得的洞见，推动了基础科学和临床应用的突破。”
Dr. Arutha Kulasinghe, Associate Professor and Clinical-oMx Lab Head, Frazier Institute, University of Queensland commented:
昆士兰大学Frazier研究所的副教授及临床oMx实验室负责人阿鲁莎·库拉辛赫博士评论道：
"Integrating ultrahigh-plex spatial proteomics into our research has been revolutionary. The platforms offered by Akoya enable us to unravel protein networks with precision and scale, opening new avenues in studying immune response and disease pathways."
“将超高通量空间蛋白组学整合到我们的研究中是一次革命性的突破。Akoya提供的平台使我们能够精确和大规模地解开蛋白质网络，为研究免疫反应和疾病通路开辟了新的途径。”
Driving Innovation and Delivering Impact
推动创新，产生影响
Akoya has consistently led the evolution of spatial proteomics, delivering impactful contributions to the global research community. The company:
Akoya不断引领空间蛋白组学的发展，为全球研究社区带来了重大的贡献。该公司：
- Delivers a spectrum of solutions, ranging from multiplex immunofluorescence technologies measuring 6-8 biomarkers to ultrahigh-plex systems capable of profiling over 100 analytes in a single experiment.
- Contributes the largest data volume to flagship global initiatives such as the Human Tumor Atlas Network (HTAN) and HuBMAP (Human BioMolecular Atlas Program).
- Powers multi-site collaborations like the MANIFEST (Multiomic Analysis of Immunotherapy Features Evidencing Success and Toxicity) program, fostering standardization and scalability in high-impact research initiatives.
- 提供一系列解决方案，从测量6-8个生物标志物的多重免疫荧光技术到能够在单次实验中分析超过100个分析物的超高通量系统。
- 为人类肿瘤图谱网络（HTAN）和人类生物分子图谱计划（HuBMAP）等旗舰全球计划提供了最大的数据信息。
- 支持像MANIFESt（免疫治疗特征多组学分析，证明成功与毒性）这样的多地点合作，促进高影响力研究项目的标准化和可扩展性。
These innovations have enabled researchers worldwide to uncover critical insights into tissue biology, contributing to potential breakthroughs in areas such as precision medicine, biomarker discovery, and therapeutic development.
这些创新使全球的研究人员能够揭示组织生物学的重要见解，为精准医疗、生物标志物发现和治疗开发等领域的潜在突破做出贡献。
Forward-Looking Statements
前瞻性声明
This press release contains forward-looking statements that are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our expectations about the potential impact of spatial biology in advancing biological research and medicine, the potential of our products and services, our ability to develop, commercialize and achieve market acceptance of our current and planned products and services and other statements regarding our business strategies and plans and objectives for future operations.
本新闻稿包含基于管理层信念和假设以及当前可用信息所做的前瞻性陈述。除历史事实外，本发布中包含的所有陈述均为前瞻性陈述，包括关于空间生物学在推动生物研究和医学中的潜在影响、我们产品和服务的潜力、我们开发、商业化和实现当前及计划产品和服务的市场接受能力及其他关于我们业务策略、计划和未来运营目标的陈述。
In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.
在某些情况下，您可以通过"可能"，"将"，"或许"，"会"，"应当"，"期望"，"打算"，"规划"，"预期"，"相信"，"估计"，"预测"，"计划"，"潜在"，"持续"，"不断"或这些词的否定形式，或其他类似术语来识别前瞻性声明，尽管并非所有前瞻性声明都含有这些词。这些声明涉及风险、不确定性和可能导致实际结果、活动水平、绩效或成就与这些前瞻性声明所表达或暗示的信息有实质不同的其他因素。这些风险、不确定性和其他因素在我们不时向证券交易委员会提交的文件中的"风险因素"，"管理讨论和分析财务状况和经营业绩"和其他地方有所描述。我们提醒您，前瞻性声明是基于我们目前已知的事实和因素以及我们对未来的预测的结合，对于这些预测，我们不能确定。因此，前瞻性声明可能不准确。本新闻稿中的前瞻性声明代表我们截至本文日期的看法。我们除法律要求外，对于任何原因不会更新任何前瞻性声明。
About Akoya Biosciences
关于Akoya Biosciences
As The Spatial Biology Company, Akoya Biosciences' mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The Company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode Panels and PhenoCycler, PhenoImager Fusion and PhenoImager HT Instruments. To learn more about Akoya, visit .
作为空间生物学公司，Akoya生命科学的使命是通过空间表型的力量将上下文带入生物学和人类健康世界。该公司提供全面的单细胞成像解决方案，使研究人员能够通过空间背景表型细胞，并可视化它们的组织和相互作用，以影响疾病进展和对治疗的反应。Akoya提供完整的空间表型解决方案，以满足发现、转化和临床研究中研究人员多样化的需求：PhenoCode Panels和PhenoCycler，PhenoImager Fusion和PhenoImager Ht仪器。要了解更多关于Akoya的信息，请访问 。
CONTACT: Investor Contact:
Priyam Shah
investors@akoyabio.com
Media Contact:
Christine Quern
cq@christinequern.com
投资者联系方式:
Priyam Shah
investors@akoyabio.com
媒体联系：
克莉丝汀·查恩
cq@christinequern.com
译文内容由第三方软件翻译。
